Acurion
San Diego
About Acurion
Acurion develops AI-driven diagnostic solutions that extract actionable genomic biomarker insights from standard pathology images to inform oncology treatment decisions. The company’s core product, OncoGaze™, analyzes digitized tumor biopsy slides to identify clinically relevant molecular features such as homologous recombination deficiency that guide therapy selection more rapidly than conventional genomic testing. Acurion’s platform integrates into existing clinical workflows to support earlier precision medicine decisions for cancer care and is being expanded to detect additional biomarkers across various tumor types. The company collaborates with research and clinical partners to advance applications of its machine learning technology in oncology and related areas.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $6.4M
- Funding stage: Seed
- Last round: Seed (Apr 2026)
- Website: acurionhealth.com
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Health Care, Health Diagnostics, Machine Learning
Social Profiles
Canonical: https://fsome.com/organization/acurion-42632 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.